A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
Br J Cancer
; 124(2): 375-382, 2021 01.
Article
in En
| MEDLINE
| ID: mdl-32994466
Full text:
1
Database:
MEDLINE
Main subject:
Camptothecin
/
Topotecan
/
Carcinoma, Ovarian Epithelial
/
Neoplasm Recurrence, Local
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Guideline
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Br J Cancer
Year:
2021
Type:
Article